FLEX TM MICROPET/SPECT/CT TO SUPPORT CANCER RES HARVARD MED:HEI:PROSTATE CANCER

这个子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是用于拨款的，而不一定是用于调查人员的机构。描述(由申请人提供)：哈佛医学院(HMS)的朗伍德医疗区(LMA)设有贝丝以色列女执事医疗中心(BIDMC)、达纳-法伯癌症研究所(DFCI)、布里格姆妇女医院(BWH)和波士顿儿童医院(CHB)，步行即可到达。在这些机构中，有数百名致力于现代癌症研究的个人。然而，目前LMA中还没有单一的小动物正电子发射断层扫描(PET)扫描仪，唯一的小动物单光子发射计算机断层扫描(SPECT)扫描仪的可用性有限，并且没有计算机断层扫描(CT)能力。如果没有microPET/CT和microSPECT/CT，现在就不可能筛选转基因动物的肿瘤形成和生长，不可能开发复制人类癌症的小鼠模型，也不可能在同一动物身上跟踪体内和纵向的治疗效果。在这项高端仪器赠款中，我们演示了如何购买一台MicroPET/SPECT/CT(FLEX？)Gamma Medica Ideas，Inc.的扫描仪，加上BIDMC承诺的110万美元以上，将能够服务于LMA癌症研究人员的需求。将该仪器放置在BIDMC的中心位置且交通便利，使NIH能够进行一项重大投资，这将使NIH资助的多个机构的众多研究项目受益。我们认为这不仅是一个将最好的资源带到我们的研究领域的机会，也是一个促进调查人员之间更大互动的机会。特别是，该仪器将服务于Lewis C.坎特利博士(BIDMC)的项目赠款，他与罗纳德·A·德皮尼奥博士(DFCI)合作，开发了基于磷脂信号转导的新型癌症转基因模型。目前，这些动物只能在尸检时进行肿瘤形成的筛查，这大大减缓了进展。随着FLEX扫描仪的安装，坎特利博士和德皮尼奥博士将能够精确定位活动物中肿瘤的位置，并跟踪他们对治疗的反应。William R.Sellers博士(DFCI)开发了几种前列腺癌的动物模型，这些模型可能会复制人类的成骨细胞病，并且使用FLEX扫描仪，将能够对这种表型进行高通量筛查。布鲁斯·R·泽特博士(CHB)是一位血管生成和肿瘤细胞归巢的专家，他终于有了一种在他的动物模型中监测新生血管和量化转移扩散的方法。Yolonda L.Colson(BWH)博士在她对移植过程中宿主细胞耐受性的研究中，将能够在体内跟踪几天到几周的白细胞。因此，在人口稠密的LMA上的这一单笔投资将实现PAR-05-124的目标，从而“对生物医学/行为研究产生重大影响，并为促进人类健康做出贡献。”

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): The Longwood Medical Area (LMA) of Harvard Medical School (HMS) houses the Beth Israel Deaconess Medical Center (BIDMC), Dana-Farber Cancer Institute (DFCI), Brigham and Women's Hospital (BWH), and Children's Hospital Boston (CHB), all within walking distance. Within these institutions are hundreds of Pis dedicated to modern cancer research. At the present time, however, there isn't a single small animal positron emission tomography (PET) scanner in the LMA, and the only small animal single photon emission computed tomography (SPECT) scanner has limited availability and no computed tomography (CT) capabilities. Without microPET/CT and microSPECT/CT, it is now impossible to screen transgenic animals for tumor formation and growth, to develop mouse models that replicate human cancer, or to follow therapeutic efficacy in vivo and longitudinally in the same animal. In this High-End Instrumentation Grant, we demonstrate how the purchase of a single trimodality microPET/SPECT/CT (FLEX?) scanner from Gamma Medica Ideas, Inc., in conjunction with a $1.1 M+ commitment from the BIDMC, will be able to service the needs of cancer researchers of the LMA. Siting this instrument in a central and easily accessible location at the BIDMC enables the NIH to make a significant investment that will benefit numerous NIH-funded research projects across multiple institutions. We see this as an opportunity not only to bring the best resources to our research area, but also as an opportunity to foster greater interaction among the investigators themselves. In particular, this instrument will service the Program Project Grant of Dr. Lewis C. Cantley (BIDMC), who in collaboration with Dr. Ronald A. De Pinho (DFCI), has developed novel transgenic models of cancer based on phospholipid signal transduction. Currently, these animals can only be screened at necropsy for tumor formation, which has greatly slowed progress. With the installation of the FLEX scanner, Drs. Cantley and De Pinho will be able to pinpoint the location of tumors in living animals, and follow their responses to treatment. Dr. William R. Sellers (DFCI) has developed several animal models of prostate cancer that could potentially replicate the osteoblastosis seen in humans, and with the FLEX scanner, would be able to perform high-throughput screening for this phenotype. Dr. Bruce R. Zetter (CHB), an expert on angiogenesis and tumor cell homing, would finally have a methodology to monitor neovascularization and to quantify metastatic spread in his animal models. Dr. Yolonda L. Colson (BWH), in her studies on host cell tolerance during transplantation, would be able to follow white blood cells over days to weeks in vivo. Thus, this single investment in the densely-populated LMA would fulfill the goal of PAR-05-124 by having a "significant impact on biomedical/behavioral research and contribute to the advancement of human health."